Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients
- 1 June 1995
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 10 (6) , 932-939
- https://doi.org/10.1002/jbmr.5650100614
Abstract
Type I collagen represents more than 90% of bone matrix. Quantitative analysis of collagen cross‐link molecules such as pyridinoline (PYD) provides valuable information on bone resorption rate. We have studied 37 hemodialysis patients who underwent a systematic transiliac bone biopsy for histomorphometry study. Eighteen of them had tetracycline double labeling, allowing to determine dynamic, in addition to static bone parameters. Measurement of serum‐free PYD was performed using a new competitive enzyme immunoassay. Serum PYD values were compared with those of three other serum markers of bone metabolism, namely intact PTH (iPTH), bone‐specific alkaline phosphatase (bAP), and osteocalcin, for the correlations with bone histomorphometric parameters. Serum PYD levels (mean ± SD) were significantly higher in dialysis patients than in normal individuals, 90.6 ± 99.6 nM versus 1.9 ± 0.4 nM, respectively. Patients with high turnover bone disease had significantly higher serum PYD levels than patients with normal or low bone turnover, 108.8 ± 108.0 nM versus 34.1 ± 12.8 nM, respectively. Serum PYD levels were positively correlated with bone resorption parameters including osteoclast surface (r = 0.59, p < 0.0001) and osteoclast number/mm2 (r = 0.61, p < 0.0001), and also with bone formation parameters, osteoblast surface (r = 0.43, p < 0.008), double‐labeled surface (r = 0.81, p < 0.001), and BFR (r = 0.91, p < 0.0001). The BFR was better correlated with serum PYD levels than with either serum iPTH or osteocalcin concentrations. However, correlation with serum bAP was comparable. Serum cross‐linked type I carboxy‐terminal telopeptide (ICTP) and type I carboxy‐terminal extension peptide (PICP) levels were also significantly increased in both groups of dialysis patients but they did not correlate with any of the bone turnover parameters. In conclusion, PYD, which is a specific serum marker of collagen breakdown, provides valuable information on bone turnover in hemodialysis patients.Keywords
This publication has 24 references indexed in Scilit:
- Procollagen type 1 C-terminal extension peptide, PTH and 1,25(0H)2D3 in chronic renal failureBone, 1993
- Immunoassay of pyridinoline crosslink excretion in normal adults and in paget's diseaseJournal of Bone and Mineral Research, 1993
- Bone turnover in malnourished childrenThe Lancet, 1992
- Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assayJournal of Bone and Mineral Research, 1992
- Bisphosphonate Kinetics in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis: Relations to Dynamic Bone Histomorphometry, Osteocalcin and Parathyroid HormoneAmerican Journal of Nephrology, 1992
- Procollagen Type I C-Terminal Extension Peptide in Predialysis Chronic Renal FailureAmerican Journal of Nephrology, 1992
- Beta2-microglobulin deposition in bone in chronic renal failureKidney International, 1991
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophyKidney International, 1986
- The Biosynthesis of Collagen and Its DisordersNew England Journal of Medicine, 1979